Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Kalytera Therapeutics Inc. (V:KLY)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for KLY within the last 6 months
See all filings within the past 6 months

Company News

Jul 27, 2021 19:55 ET
Claritas Announces Grant of Stock Options to Directors and Officers
Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the "Company" or "Claritas") announced that it granted stock options on July 23, 2021 to the directors and officers of the Company. The stock options have an exercise price...
Read full article
Jul 26, 2021 07:15 ET
Claritas Cites Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe COVID-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107
Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that a recently published study led by clinicians at Royal Brompton & Harefield NHS Foundation Trust1 validates the potential of the...
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Mar 31, 202131,188-705,702
Mar 15, 2021736,890724,036
Feb 28, 202112,8546,168
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a clinical stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for patients with unmet medical needs. The Company is engaged in developing R-107 for the treatment of vaccine-resistant corona virus disease (COVID) strains. R-107 is a patented nitric oxide-releasing compound for treatment of Covid-19 infection and possible prevention of, other viral infections. R-107 is designed to augment the body's natural release of nitric oxide to significantly hasten and strengthen the body's ability to combat viruses. IT is also developing CLA-1816 to provide effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

See business summary



Search (past week) for $KLY.CA KLY.V

  • No tweets found